Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

Faced with the novelty of a 212Pb-labeled monoclonal antibody (mAb) for clinical translation, concerns were expressed by the Food and Drug Administration (FDA) regarding 212Pb prematurely released from the mAb-chelate conjugate. The objective of this study was to simulate the worst case scenario of such a failure. Groups of Balb/c mice (n = 9–20) were administered 212Pb by intraperitoneal (0.0925–1.85 MBq) or intravenous (0.0925–1.11 MBq) injection and then euthanized at 7 or 90 days to assess acute or chronic effects. Weights were recorded prior to injection of the 212Pb and at the end of the observation periods. Blood samples were collected for clinical chemistry and blood cell analysis. Thirty tissues were harvested and formalin fixed for histopathological examination. Treatment related effects of the 212Pb were observed in the bone marrow, spleen, kidneys and the liver. Histological alterations in these organs were considered mild to moderate, indicating low grade toxicity, and not considered severe enough to affect function. This data was presented to the FDA and determined to be acceptable. The clinical trial with 212Pb-TCMC-trastuzumab was approved in January 2011 and the trial opened at the University of Alabama at Birmingham (UAB) in July.

[1]  A. Buha,et al.  Insight into the oxidative stress induced by lead and/or cadmium in blood, liver and kidneys. , 2015, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[2]  M. Brechbiel,et al.  Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease , 2015, mAbs.

[3]  J. Chung,et al.  Erythrophagocytosis of Lead-Exposed Erythrocytes by Renal Tubular Cells: Possible Role in Lead-Induced Nephrotoxicity , 2014, Environmental health perspectives.

[4]  Julien Torgue,et al.  Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab , 2014, The Journal of Nuclear Medicine.

[5]  M. Brechbiel,et al.  Impact of α-Targeted Radiation Therapy on Gene Expression in a Pre-Clinical Model for Disseminated Peritoneal Disease when Combined with Paclitaxel , 2014, PloS one.

[6]  S. Shen,et al.  Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. , 2014, Cancer biotherapy & radiopharmaceuticals.

[7]  M. Brechbiel,et al.  Gene expression profiling upon 212Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model , 2013, Cancer medicine.

[8]  I. Navarro-Teulon,et al.  Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 2 1 2Pb , 2013, PloS one.

[9]  M. Brechbiel,et al.  Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. , 2013, Cancer biotherapy & radiopharmaceuticals.

[10]  S. Shen,et al.  First in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab , 2013 .

[11]  M. Brechbiel,et al.  212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint , 2013, British Journal of Cancer.

[12]  M. Brechbiel,et al.  Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. , 2013, International journal of radiation oncology, biology, physics.

[13]  Nathan Schneider,et al.  Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. , 2012, International journal of oncology.

[14]  M. Brechbiel,et al.  212Pb-Radioimmunotherapy Induces G2 Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease , 2012, Molecular Cancer Therapeutics.

[15]  D. Weiner,et al.  Chronic kidney disease associated with environmental toxins and exposures. , 2010, Advances in chronic kidney disease.

[16]  M. Brechbiel,et al.  Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease , 2008, Clinical Cancer Research.

[17]  R. Guilard,et al.  New Insights into the Complexation of Lead(II) by 1,4,7,10‐Tetrakis(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecane (DOTAM): Structural, Thermodynamic, and Kinetic Studies , 2008 .

[18]  M. Brechbiel,et al.  Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease , 2007, Clinical Cancer Research.

[19]  M. Brechbiel,et al.  Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. , 2005, Cancer biotherapy & radiopharmaceuticals.

[20]  Christine Ruehl-Fehlert,et al.  Revised guides for organ sampling and trimming in rats and mice--Part 3. A joint publication of the RITA and NACAD groups. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[21]  T. Waldmann,et al.  Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  L. Chappell,et al.  Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. , 2000, Nuclear medicine and biology.

[23]  M. Brechbiel,et al.  In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand , 1998, European Journal of Nuclear Medicine.

[24]  T. Waldmann,et al.  Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  W C Eckelman,et al.  Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment. , 1997, Bioconjugate chemistry.

[26]  M J Welch,et al.  Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. , 1995, Cancer research.

[27]  S. Larson,et al.  Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. , 1990, Cancer research.

[28]  S. Larson,et al.  Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.